Table 1.
Baseline characteristics.
| Complete Cytoreduction | Incomplete Cytoreduction | Total | p Value | |
|---|---|---|---|---|
| n = 41 (82%) | n = 9 (18%) | n = 50 | ||
| Mean Age (years) | 66 (43–82) | 67 (57–75) | 66 (43–82) | |
| Mean CA 125 (U/mL) | 0.06 | |||
| Pre NACT | 1767 (242–1380) | 1254 (340–4414) | 1673 (242–4414) | |
| Post NACT | 348 (9–883) | 440 (28–2164) | 365 (9–2164) | |
| FIGO stage | 0.9 | |||
| III | 32 (78%) | 7 (55%) | 39 (78%) | |
| IV | 9 (22%) | 2 (22%) | 11 (22%) | |
| Surgical complications | 0.04 | |||
| No complications | 33 (81%) | 6 (67%) | 39% (78%) | |
| Clavien–Dindo < 3 | 7 (17%) | 2 (22%) | 9 (18%) | |
| Clavien–Dindo ≥ 3 | 1 (2%) | 1 (11%) | 2 (4%) | |
| CRS | 0.08 | |||
| CRS 1/2 | 30 (73%) | 9 (100%) | 39 (78%) | |
| CRS 3 | 11 (27%) | - | 11 (22%) | |
| Median PCI (Range) | 0.01 | |||
| Before NACT | 27 (13–36) | 25 (17–35) | 26 (13–36) | |
| ICS | 13 (1–25) | 19 (13–27) | 15 (1–27) | |
| Delta PCI | 12 (7–29) | 8 (4–11) | 11 (4–29) | |
| BRCA status | 0.06 | |||
| Mut | 6 | 4 | 10 | |
| WT | 35 | 5 | 40 |
NACT: neoadjuvant chemotherapy; CRS: chemotherapy response score; PCI: peritoneal cancer index.